Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Celgene Corporation Prologue Research International |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00179699 |
Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.
Condition | Intervention | Phase |
---|---|---|
Non-Small Cell Lung Cancer |
Drug: CC-5013 Drug: pemetrexed |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Factorial Assignment, Safety Study |
Official Title: | Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer |
Estimated Enrollment: | 40 |
Study Start Date: | September 2005 |
Estimated Study Completion Date: | November 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Any of the following laboratory abnormalities:
United States, Florida | |
MD Anderson - Orlando | |
Orlando, Florida, United States, 32806 | |
United States, Iowa | |
University of Iowa | |
Iowa City, Iowa, United States, 52242 | |
United States, Kentucky | |
Norton Healthcare | |
Louisville, Kentucky, United States, 40202 | |
United States, Missouri | |
Washington University | |
St. Louis, Missouri, United States, 63110 | |
United States, New York | |
North Shore Hem/Onc Associates | |
East Setauket, New York, United States, 11733-3456 |
Study ID Numbers: | CC-5013-NSCL-002 |
Study First Received: | September 10, 2005 |
Last Updated: | November 2, 2005 |
ClinicalTrials.gov Identifier: | NCT00179699 |
Health Authority: | United States: Food and Drug Administration |
cc-5013 Non Small Cell Lung Cancer revlimid celgene cc5013 |
Folic Acid Pemetrexed Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Lenalidomide Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Antimetabolites Respiratory Tract Neoplasms Neoplasms Antimetabolites, Antineoplastic Neoplasms by Site Neoplasms by Histologic Type |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Folic Acid Antagonists Pharmacologic Actions |